459 related articles for article (PubMed ID: 20627289)
1. HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer--re-TURBT recurrence rates in a prospective, randomized study.
Geavlete B; Jecu M; Multescu R; Georgescu D; Geavlete P
Urology; 2010 Sep; 76(3):664-9. PubMed ID: 20627289
[TBL] [Abstract][Full Text] [Related]
2. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
3. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
5. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
[TBL] [Abstract][Full Text] [Related]
6. Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?
Karaolides T; Skolarikos A; Bourdoumis A; Konandreas A; Mygdalis V; Thanos A; Deliveliotis C
Urology; 2012 Aug; 80(2):354-9. PubMed ID: 22857752
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
[TBL] [Abstract][Full Text] [Related]
8. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
[TBL] [Abstract][Full Text] [Related]
9. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
10. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Lotan Y; Chaplin I; Ahmadi H; Meng X; Roberts S; Ladi-Seyedian S; Bagrodia A; Margulis V; Woldu S; Daneshmand S
BJU Int; 2021 Jan; 127(1):108-113. PubMed ID: 32648957
[TBL] [Abstract][Full Text] [Related]
12. [Is a routine second transurethral resection of the bladder still necessary after hexaminolévulinate photodynamic diagnosis-assisted TURBT?].
Doisy L; Walz J; Fakhfakh S; Rybikowski S; Koskas Y; Gravis G; Pignot G
Prog Urol; 2019; 29(6):332-339. PubMed ID: 31104952
[TBL] [Abstract][Full Text] [Related]
13. Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors--results of a prospective, randomized comparison to the standard approach.
Geavlete B; Multescu R; Georgescu D; Stanescu F; Jecu M; Geavlete P
Urology; 2012 Apr; 79(4):846-51. PubMed ID: 22342408
[TBL] [Abstract][Full Text] [Related]
14. Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden.
Dansk V; Malmström PU; Bläckberg M; Malmenäs M
Future Oncol; 2016; 12(8):1025-38. PubMed ID: 26975197
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
[TBL] [Abstract][Full Text] [Related]
16. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Stenzl A; Burger M; Fradet Y; Mynderse LA; Soloway MS; Witjes JA; Kriegmair M; Karl A; Shen Y; Grossman HB
J Urol; 2010 Nov; 184(5):1907-13. PubMed ID: 20850152
[TBL] [Abstract][Full Text] [Related]
17. Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience.
Lacetera V; Cantoro U; Montesi L; Cantoro D; Cervelli B; Cicetti A; Gabrielloni G; Milella D; Montesi M; Morcellini R; Parri G; Recanatini E; Beatrici V
Arch Ital Urol Androl; 2017 Mar; 89(1):39-41. PubMed ID: 28403596
[TBL] [Abstract][Full Text] [Related]
18. 'Real-life experience': recurrence rate at 3 years with Hexvix
Gallagher KM; Gray K; Anderson CH; Lee H; Stewart S; Donat R; Mariappan P
World J Urol; 2017 Dec; 35(12):1871-1877. PubMed ID: 28803385
[TBL] [Abstract][Full Text] [Related]
19. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
